OTTAWA, Feb. 15, 2018 /Weed Wire/ — As part of its ongoing efforts to provide Canadian pharmacists with practice tools and resources, CPhA has developed a new medical cannabis evidence guide.
Tag Archives: cannabinoids
Cannabis scientists may want to start planning for a trip to the Holy Land. The International Cannabinoid Research Society, the longest running scientific society focused on cannabis research, has picked Jerusalem for the site of its annual International Symposium on the Cannabinoids in 2021.
NEW YORK, June 23, 2017 /Weed Wire/ — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the company filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent of invention that involves a chewing gum composition with controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment.
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
The combination of cannabinoids and chemotherapy could be the key to improving cancer treatment. This is according to a new study published in the International Journal of Oncology on May 29, 2017.
On May 23, 2017, two retail shops were sued by Wisconsin’s departments of justice and consumer protection. The Milwaukee stores broke the law as they falsely advertised synthetic THC as household products.
Can this prolonged low-dose treatment with a compound in marijuana help reverse memory loss and improve cognitive skills? Researchers say it could.
Here are 4 top stocks in the growing medical marijuana industry that have a tremendous amount of potential for investors.
A west New York-based biotech company has successfully grown a strain of marijuana that contains zero THC, a feat the company says will transform the medical marijuana industry.
Oxford University, one of the oldest and most prestigious universities in the world, recently announced that it is launching a program to research the therapeutic benefits of cannabinoids in the treatment of cancer, inflammatory disease and pain.
In the last trading session, the stock price of Medical Marijuana Inc (OTCMKTS:MJNA) declined more than 8% to close the day at $0.112. The decline came at a share volume of 24.74 million compared to average share volume of 17.32 million.
“Cannabis in Parkinson’s Disease: Growing Like a Weed!” was presented at the University of Colorado School of Medicine’s Neurology Grand Rounds on Jan. 18, 2017.
A comprehensive study slams many of the alleged benefits of marijuana and points to serious negative effects. What will the impact of this study be for marijuana stocks?
On Dec. 14, 2016, the United States Drug Enforcement Administration announced a new rule that makes hemp-based cannabidiol a federally illegal substance. Under the new rules, liquid extracts derived from plants of the cannabis genus that contain one or more cannabinoids are now considered a schedule I substance.
DENVER, Dec. 15, 2016 /Weed Wire/ — On December 13, 2016, the DEA issued its Final Rule, “Establishment of New Drug Code for Marihuana Extract,” which serves to potentially devastate developing businesses and consumer, textile and manufacturing industries related to cannabinoids.
Cannabinoids – what are they? How do they affect the human body? Are they really medicinal? On Nov. 16, 2016, Marijuana Investor Summit is bringing the Science and Medicine of Cannabis to the Palms Casino Resort in Las Vegas, Nevada, to answer these questions and more.
On Oct. 24, 2016, Alaska’s first marijuana testing lab opened for business. CannTest LLC, in Ship Creek, opened its doors at 10:30 a.m. and was immediately met with 15 samples to test from two marijuana cultivators — Greatland Ganja and Green Rush Gardens LLC.
NEW YORK, Oct. 20, 2016 /Weed Wire/ — New research is providing a more detailed view into the structure of the human cannabinoid (CB1) receptor.
LAS VEGAS, Sept. 15, 2016 /Weed Wire/ — Skinvisible Pharmaceuticals, Inc., (OTCQB: SKVI), developers of patented Invisicare® polymer delivery systems, announces it has licensed the exclusive world rights to its topical and transdermal cannabis products formulated with Invisicare to CannaSkin, LLC, a cannabis product licensing company with international contacts in the medical marijuana industry.
Medical marijuana advocate and former Baltimore Ravens player Eugene Monroe published his first column for The Cannabist on Aug. 1, 2016. “On a mission to get the NFL to accept cannabinoids as a viable option for pain,” says part of Monroe’s biographical information at the end of the column. The Baltimore Ravens released Monroe in June 2016.
IRVINE, Calif., July 29, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce they will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers.
While marijuana may be the culprit of some short term memory loss, new research seems to suggest that an active chemical in the substance, THC, may be the key in the prevention and treatment of Alzheimer’s disease.
LOS ANGELES, June 30, 2016 /Weed Wire/ — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced the relocation of their corporate headquarters to Irvine, California.
The Ravens wouldn’t draft a left tackle who they knew was smoking marijuana through a gas mask. But a left tackle who is on their roster for now has made a major contribution to marijuana research.
On April 20, 2016, Chooze Corp. launched its first product, LucidMood, a line of vaporizable pucks infused with terpenes, distinctive aromatic compounds, that induce immediate shifts in the individual moods of those who have THC in their systems.
Chooze Corp. develops Mood-enhancing Cannabis products — brands that deliver the mood-enhancing effects of cannabis in the safest, healthiest, most environmentally conscious way possible. Our first product, LucidMood, is a line of terpene-infused vaporizable pucks that produce an immediate shift in the mood of anyone who has THC in their system.
The vast healing properties of the cannabis plant are becoming more and more widely known. The actual scientific knowledge behind why and how cannabinoids are an invaluable treatment and medication is sadly not widespread.
Evoxe Laboratories creates cannabis vaporizer pens specifically formulated to enhance the natural properties of cannabinoids for a dynamic, consistent, and therapeutic experience.
On Tuesday, Nov. 17, 2015, the International Paralympic Committee announced that it has suspended Alexander Zverev, a Russian Paralympic sprinter, for violating a rule of the World Anti-Doping Agency.
LAS VEGAS, Oct. 9, 2015 /PRNewswire/ — DigiPath Labs, a subsidiary of DigiPath, Inc.(OTCBB and OTCQB: DIGP), recently successfully completed voluntary proficiency testing of its ability to detect cannabinoids and terpenoids, accurately identifying potency levels of five cannabinoids and 10 terpenoids in unknown samples.
A recent breakthrough made by researchers from the Technical University of Dortmund in Germany could hold the key to unlocking the secrets of the healing effects of marijuana.
Because research is relatively underdeveloped in the segment of cannabis for pet health, there is ample opportunity for companies to find a strong foothold and ultimately stake claim to this market.
A recent study seems to back up claims made by parents and patients that medical marijuana could help intractable seizures.
LOS ANGELES, Aug. 24, 2015 /PRNewswire/ — Evoxe Laboratories, the new and pioneering developer of medicinal cannabis consumption technologies, today announces their debut product offerings in California, as well as partnerships with Sacramento’s TBD Music Festival and Irvine’s Safe In Sound Festival this September.
No matter how much “counterculture” stereotypes continue to permeate parts of the industry if not the overall debate, the bottom line in the marijuana business is getting increasingly technical, medical and bottom line.
It has been a bit of a dry spell for decent IPOs in the cannabis space. But the rains have come down with the initial public offering of Devon, Pennsylvania-based Zynerba Pharmaceuticals (NASDAQ: ZYNE).
When people say “medical marijuana,” they often think of cancer patients, people suffering from PTSD, or persons struggling with chronic pain. There is a huge laundry list of ailments that medical marijuana can purportedly treat, and the newest addition to that list is broken bones.
MyDx’s hardware/software ecosystem has a very easy value proposition to dish out: simple, instant testing of solids, liquids and gases to measure their positive attributes, and whether there’s any pesticides or other no-gooders in your food, water and air.
NEW YORK, N.Y., June 17, 2015 /PR Newswire/ — CannaPharmaRx (OTCQB:CPMD), a leader in the research, development, and commercialization of cannabinoid-based drug products, is pleased to announce that it will be exhibiting at the 2nd Annual Cannabis World Congress & Business Expo. The conference will be held at the Jacob Javits Center in New York, NY from Wednesday, June 17 through Friday, June 19. CannaPharmaRx will exhibit in booth # 316.
Science crowdfunding startup Walacea is helping Madrid’s MedicalCannabis Bike Tour to raise the final €85,000 it needs to conduct an independent clinical trial into the effect of cannabinoids on brain tumours.
It is often thought that the economic future for recreational marijuana is relatively limited. The people who use it for fun will eventually move from the black market to the legal market.
Oxis Biotech, a subsidiary of Oxis International (OTCQB: OXIS), recently filed a notification to shareholders and the SEC that the company would be entering into a reverse split of not less than 1-50 shares and not more than 1-250 shares.
Two Colorado companies, Apothecanna, and Mary Jane’s Medicinals are at the forefront of the topicals movement.
When a pair of British doctors set out to make medicines from the cannabis plant 16 years ago, they knew it would take some time to crack the world’s biggest pharmaceuticals market.